Cargando…

Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab

Lynch syndrome is caused by mutations in mismatch repair genes that lead to microsatellite instability (MSI). An increased number of mutation-associated neoantigens have been observed in patients with high-frequency MSI (MSI-H) cancer; in addition, membranous programmed death ligand-1 (PD-L1) tends...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawashima, Yosuke, Nishikawa, Shingo, Ninomiya, Hironori, Yoshida, Reiko, Takano, Natsuki, Oguri, Tomoyo, Kitazono, Satoru, Yanagitani, Noriko, Horiike, Atsushi, Ohyanagi, Fumiyoshi, Ishikawa, Yuichi, Nishio, Makoto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548921/ https://www.ncbi.nlm.nih.gov/pubmed/31092773 http://dx.doi.org/10.2169/internalmedicine.1673-18

Ejemplares similares

EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer
por: Sonoda, Tomoaki, et al.
Publicado: (2018)

Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms
por: Yanagitani, Noriko, et al.
Publicado: (2020)

Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non–small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020‐02)
por: Tanaka, Hisashi, et al.
Publicado: (2022)

Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first‐line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021‐01)
por: Uematsu, Shinya, et al.
Publicado: (2022)

Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients
por: Kitazono, Satoru, et al.
Publicado: (2019)

Distinct Characteristics of Small Cell Lung Cancer Correlate With Central or Peripheral Origin: Subtyping Based on Location and Expression of Transcription Factor TTF-1
por: Miyauchi, Eisaku, et al.
Publicado: (2015)

Prognostic value of (18)F‐fluoroazomycin arabinoside PET/CT in patients with advanced non‐small‐cell lung cancer
por: Saga, Tsuneo, et al.
Publicado: (2015)

Phase II trial of S‐1 treatment as palliative‐intent chemotherapy for previously treated advanced thymic carcinoma
por: Okuma, Yusuke, et al.
Publicado: (2020)

Prognostic significance of CpG island methylator phenotype in surgically resected small cell lung carcinoma
por: Saito, Yuichi, et al.
Publicado: (2016)

Monitoring epidermal growth factor receptor C797S mutation in Japanese non–small cell lung cancer patients with serial cell‐free DNA evaluation using digital droplet PCR
por: Ariyasu, Ryo, et al.
Publicado: (2021)

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
por: Katayama, Ryohei, et al.
Publicado: (2015)

Clinical influence of switching companion diagnostic tests for EGFR‐TKs from Therascreen to Cobas v2
por: Uchibori, Ken, et al.
Publicado: (2021)

Clinical characteristics of patients with KRAS mutation detected by liquid biopsy
por: Amino, Yoshiaki, et al.
Publicado: (2023)

Feasibility of next‐generation sequencing test for patients with advanced NSCLC in clinical practice
por: Ariyasu, Ryo, et al.
Publicado: (2020)

Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients
por: Nishio, M, et al.
Publicado: (2005)

Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors
por: Tozuka, Takehiro, et al.
Publicado: (2020)

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity
por: Yoshizawa, Takahiro, et al.
Publicado: (2021)

Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors
por: Ariyasu, Ryo, et al.
Publicado: (2023)

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
por: Horiike, A, et al.
Publicado: (2011)

Durable benefit and change in TCR clonality with nivolumab in a Lynch syndrome–associated glioma
por: Cabezas-Camarero, Santiago, et al.
Publicado: (2022)

Relationship Between Pathologic T1 Categories and Pathologic Factors Affecting Prognosis in Pulmonary Adenocarcinoma
por: Ninomiya, Hironori, et al.
Publicado: (2022)

Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib
por: Sakamoto, Hiroaki, et al.
Publicado: (2021)

Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation
por: Sagawa, Ray, et al.
Publicado: (2022)

A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630
por: Taniguchi, Yuri, et al.
Publicado: (2022)

Poor efficacy of anti‐programmed cell death‐1/ligand 1 monotherapy for non‐small cell lung cancer patients with active brain metastases
por: Tozuka, Takehiro, et al.
Publicado: (2020)

Characteristics of surgically resected non‐small cell lung cancer patients with post‐recurrence cure
por: Sonoda, Dai, et al.
Publicado: (2020)

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
por: Okada, Koutaroh, et al.
Publicado: (2019)

Relationship of tumor PD‐L1 (CD274) expression with lower mortality in lung high‐grade neuroendocrine tumor
por: Inamura, Kentaro, et al.
Publicado: (2017)

A case of strongly suspected Lynch syndrome with colorectal neuroendocrine carcinoma
por: Kobayashi, Naoya, et al.
Publicado: (2022)

Lynch Syndrome-Related Clear Cell Carcinoma of the Cervix: A Case Report
por: Nakamura, Kohei, et al.
Publicado: (2018)

Charles Lynch and His Vestigial Legacy—Workplace Lynching
por: Ramasubban, Suresh
Publicado: (2019)

The Statesboro Lynching
Publicado: (1904)

Primary malignant melanoma of the esophagus successfully treated with nivolumab: a case report
por: Ito, Shingo, et al.
Publicado: (2021)

Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment
por: Furune, Satoshi, et al.
Publicado: (2021)

Readministration of Nivolumab after Persistent Immune-related Colitis in a Patient with Recurrent Melanoma
por: Fujii, Yosuke, et al.
Publicado: (2017)

Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab
por: Senoo, Satoru, et al.
Publicado: (2018)

An extremely rare case of rapidly growing mediastinal well-differentiated liposarcoma with a sclerosing variant: a case report
por: Iwamoto, Naoya, et al.
Publicado: (2020)

Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with Genexus™ integrated sequencer
por: Low, Siew-Kee, et al.
Publicado: (2022)

Correction to: Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment
por: Furune, Satoshi, et al.
Publicado: (2021)

Lynch syndrome (HNPCC)
por: Kładny, Józef, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_aqj0r5hjmcbsi6fo2udq8t6iuf